Home>IPO>Windlas Biotech Ltd.

Windlas Biotech IPO

Windlas Biotech Ltd.

₹13,440 /30 sharesMinimum Investment

IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE & NSE₹460₹437-₹23.00 (5.00%)

IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
4 Aug ‘21 - 6 Aug ‘21₹13,44030₹448 - ₹460
Issue SizeIPO Doc
401.53Cr
RHP PDFopen_in_new

Subscription Rate As on 6th Aug 2021, 8:00 PM

  • Retail Individual Investor
    24.27x
  • Non-Institutional Investor
    15.73x
  • Qualified Institutional Buyers
    24.40x

About Company

Windlas Biotech Ltd. is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances, and low solubility, the company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing, and commercial manufacturing of generic products, including complex generics.
... Read More
Parent Organisation
Windlas Biotech Ltd.
Founded
2000
Managing Director
Hitesh Windlass

Strengths & Risks

  • add
    A leading CDMO in India with a focus on the chronic therapeutic category.
  • add
    Innovative portfolio of complex generic products supported by robust R&D capabilities.
  • add
    Efficient and quality compliant manufacturing facilities with significant entry barriers.
  • add
    Strong and long-term relationships with leading Indian pharmaceutical companies.
  • add
    Consistent track record of financial performance.
  • add
    Experienced Promoters with a strong management team.
  • remove
    Dependency on the success of its relationships with its CDMO customers, including leading Indian pharmaceutical companies and multinational companies.
  • remove
    Any failure to comply with the quality standards and technical specifications prescribed by its CDMO customers.
  • remove
    Inability to identify and understand evolving industry trends, technological advancements, customer preferences, regulatory change, and innovate new products to meet customers’ demands.
  • remove
    Continuing impact of the outbreak of the COVID-19.
  • remove
    Highly competitive market.
  • remove
    Inability to meet any contractual obligations imposed by the CDMO agreements.
  • remove
    Insufficient cash flows from its operations or inability to borrow to meet its working capital requirements.
  • remove
    Non-compliance with the applicable environmental and workers’ health and safety laws and regulations.
  • remove
    Manufacturing operations are geographically concentrated in Dehradun, Uttarakhand.
  • remove
    Dependency on third-party qualified contract research organizations to conduct clinical trials and studies of the company’s new products.
  • remove
    Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimbursement, and related matters.
  • remove
    Inability to protect its intellectual property and proprietary information.
  • remove
    Any unscheduled, unplanned, or prolonged disruption of its manufacturing operations, such as strikes and lockouts.
  • remove
    Any shortfall in the supply of its raw materials or an increase in the raw material costs, or other input costs.
  • remove
    Risks associated with rejection of supplied products, and consequential claims, and associated product liability costs due to defects in its product.

Financials

*All values are in Rs. Cr
No Graph Data To Display
ⓒ 2016-2021 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 1.9.0
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES: ICICI PRUDENTIAL  | HDFC  | NIPPON INDIA  | ADITYA BIRLA SUN LIFE  | SBI  | UTI  | FRANKLIN TEMPLETON  | KOTAK MAHINDRA  | IDFC  | DSP  | AXIS  | TATA  | L&T  | SUNDARAM  | PGIM  | INVESCO  | LIC  | JM FINANCIAL  | BARODA PIONEER  | CANARA ROBECO  | HSBC  | IDBI  | INDIABULLS  | MOTILAL OSWAL  | BNP PARIBAS  | MIRAE ASSET  | PRINCIPAL  | BOI AXA  | UNION KBC  | TAURUS  | EDELWEISS  | NAVI  | MAHINDRA  | QUANTUM  | PPFAS  | IIFL  | Quant  | SHRIRAM  | SAHARA | ITI
ABOUT GROWW
keyboard_arrow_down
arrow_drop_down_circle